Carvedilol
- Generic Name
- Carvedilol
- Brand Names
- Coreg
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N2O4
- CAS Number
- 72956-09-3
- Unique Ingredient Identifier
- 0K47UL67F2
- Background
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs ...
- Indication
Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.
- Associated Conditions
- Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
- Associated Therapies
- -
Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
- Conditions
- Interventions
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 56
- Registration Number
- NCT01798992
- Locations
- 🇺🇸
University of Colorado Hospital, Denver, Colorado, United States
🇺🇸University of Utah Medical Center, Salt Lake City, Utah, United States
Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity
- Conditions
- Interventions
- First Posted Date
- 2012-11-09
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 200
- Registration Number
- NCT01724450
- Locations
- 🇧🇷
Heart Institute University of Sao Paulo, Sao Paulo, Brazil
Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children
- First Posted Date
- 2012-11-07
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- The Hospital for Sick Children
- Registration Number
- NCT01723371
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Registration Number
- NCT01659346
- Locations
- 🇮🇳
Institute of Liver and Biliary Sciences, New Delhi, Delhi, India
Beta Blocker Therapy in Moderate to Severe COPD
- Conditions
- Interventions
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 18
- Registration Number
- NCT01656005
- Locations
- 🇬🇧
Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom
Carvedilol for Prevention of Paroxysmal Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 300
- Registration Number
- NCT01608893
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Use of Beta-blockers and Risk of New Onset Diabetes
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12336
- Registration Number
- NCT01587638
PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT01586156
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition
- Conditions
- Interventions
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- IPCA Laboratories Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT01577914
- Locations
- 🇮🇳
Accutest Research Lab (I) Pvt. Ltd., Ahmedabad, Gujarat, India
Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease
- Conditions
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.